Biotechnology companies like those started by Dartmouth’s Tillman Gerngross continue to develop new ways to discover and engineer antibodies for use as therapeutics, The Scientist reports.
Gerngross, the associate provost of Entrepreneurship & Technology Transfer and a professor of bioengineering at Thayer School of Engineering, has started several biotech companies, including Adimab, the article notes. “It’s a great time to be in this space,” Gerngross tells The Scientist.
The first of Adimab’s antibody therapies is headed into clinical trials, the article notes. “Gerngross’s success is not only a tribute to his company’s technology, but an indication of the industry’s continued thirst for new antibodies,” the magazine writes.
Read the full story, published 9/1/13 by The Scientist.